Zampilimab

DRUG2 trials

Sponsors

UCB Biopharma SRL

Conditions

Chronic Allograft InjuryHealthy Study Participants

Phase 1

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury

TerminatedNCT04335578

UCB Biopharma SRLChronic Allograft Injury

Start: 2019-10-21End: 2022-05-04Updated: 2022-09-21

A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants

CompletedNCT04705350

UCB Biopharma SRLHealthy Study Participants

Start: 2021-01-11End: 2021-07-28Updated: 2022-07-19

Related Papers

Amelioration of Fibrotic Remodeling of Human 3‐Dimensional Full‐Thickness Skin by Transglutamase 2 Inhibition

Arthritis & Rheumatology2023-04-1411 citations